Date: 2012-11-13
Type of information: Commercialisation agreement
Compound: ChondroCelect®
Company: Tigenix (Belgium) Genpharm Services (Dubai - United Arab Emirates)
Therapeutic area: Bone diseases
Type agreement: commercialisation
distribution
Action mechanism: ChondroCelect® is an autologous, individualized cell therapy.
Disease: symptomatic cartilage defects of the knee
Details: TiGenix and pharmaceutical marketing and distribution company Genpharm in Dubai, United Arab Emirates, have signed an exclusive agreement for the commercialization of ChondroCelect® in the Middle East region. TiGenix and Genpharm have entered into an exclusive distribution agreement to facilitate the successful commercialization of ChondroCelect® in Saudi Arabia, UAE, Kuwait, Bahrain, Qatar, Oman (GCC), Lebanon, Jordan, Syria, Iraq, Iran and Egypt. Under the terms of the agreement, Genpharm will facilitate patients\' access to ChondroCelect® in the Middle East countries by obtaining the required regulatory approvals, and providing training and product support to surgeons and healthcare professionals in selected orthopedic centers. TiGenix continues to be the marketing authorisation holder and will be responsible for logistics and the manufacturing of ChondroCelect®.
Financial terms:
Latest news:
